217 related articles for article (PubMed ID: 7634504)
41. Effect of growth hormone on bone status in growth hormone-deficient adults.
Kuzma M; Homerova Z; Dlesk A; Koller T; Killinger Z; Vanuga P; Lazurova I; Tomkova S; Payer J
Bratisl Lek Listy; 2013; 114(12):689-95. PubMed ID: 24329506
[TBL] [Abstract][Full Text] [Related]
42. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
43. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults.
Beshyah SA; Kyd P; Thomas E; Fairney A; Johnston DG
Clin Endocrinol (Oxf); 1995 Mar; 42(3):249-54. PubMed ID: 7758229
[TBL] [Abstract][Full Text] [Related]
44. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD.
Baroncelli GI; Bertelloni S; Sodini F; Saggese G
Clin Endocrinol (Oxf); 2004 Feb; 60(2):175-84. PubMed ID: 14725678
[TBL] [Abstract][Full Text] [Related]
45. TRABECULAR BONE SCORE CHANGE DIFFERS WITH REGARD TO 25(OH)D LEVELS IN PATIENTS TREATED FOR ADULT-ONSET GROWTH HORMONE DEFICIENCY.
Kužma M; Binkley N; Bednárová A; Killinger Z; Vaňuga P; Payer J
Endocr Pract; 2016 Aug; 22(8):951-8. PubMed ID: 27042750
[TBL] [Abstract][Full Text] [Related]
46. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
47. Bone mineral density and circulating cytokines in patients with acromegaly.
Longobardi S; Di Somma C; Di Rella F; Angelillo N; Ferone D; Colao A; Merola B; Lombardi G
J Endocrinol Invest; 1998 Nov; 21(10):688-93. PubMed ID: 9854685
[TBL] [Abstract][Full Text] [Related]
48. Factors influencing the desire for long-term growth hormone replacement in adults.
Holmes SJ; Shalet SM
Clin Endocrinol (Oxf); 1995 Aug; 43(2):151-7. PubMed ID: 7554309
[TBL] [Abstract][Full Text] [Related]
49. Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis.
Tritos NA; Hamrahian AH; King D; Greenspan SL; Cook DM; Jönsson PJ; Koltowska-Häggstrom M; Biller BM
Clin Endocrinol (Oxf); 2013 Aug; 79(2):178-84. PubMed ID: 23278636
[TBL] [Abstract][Full Text] [Related]
50. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass.
Saggese G; Baroncelli GI; Bertelloni S; Barsanti S
J Clin Endocrinol Metab; 1996 Aug; 81(8):3077-83. PubMed ID: 8768878
[TBL] [Abstract][Full Text] [Related]
51. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
52. Effect of resistance exercise and growth hormone on bone density in older men.
Yarasheski KE; Campbell JA; Kohrt WM
Clin Endocrinol (Oxf); 1997 Aug; 47(2):223-9. PubMed ID: 9302398
[TBL] [Abstract][Full Text] [Related]
53. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults.
Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Shalet SM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):749-57. PubMed ID: 10468947
[TBL] [Abstract][Full Text] [Related]
54. Abnormalities in bone mineral density distribution and bone scintigraphy in patients with childhood onset hypopituitarism.
Kosowicz J; El Ali Z; Ziemnicka K; Sowinski J
J Clin Densitom; 2007; 10(3):332-9. PubMed ID: 17470407
[TBL] [Abstract][Full Text] [Related]
55. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency.
Elbornsson M; Götherström G; Bosæus I; Bengtsson BÅ; Johannsson G; Svensson J
Eur J Endocrinol; 2012 May; 166(5):787-95. PubMed ID: 22318746
[TBL] [Abstract][Full Text] [Related]
56. Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents.
Fors H; Bjarnason R; Wirént L; Albertsson-Wikland K; Bosaeust L; Bengtsson BA; Johannsson G
Clin Endocrinol (Oxf); 2001 Nov; 55(5):617-24. PubMed ID: 11894973
[TBL] [Abstract][Full Text] [Related]
57. Impact of the growth hormone replacement on bone status in growth hormone deficient adults.
Kužma M; Kužmová Z; Zelinková Z; Killinger Z; Vaňuga P; Lazurová I; Tomková S; Payer J
Growth Horm IGF Res; 2014 Feb; 24(1):22-8. PubMed ID: 24382377
[TBL] [Abstract][Full Text] [Related]
58. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3.
Bing-You RG; Denis MC; Rosen CJ
Calcif Tissue Int; 1993 Mar; 52(3):183-7. PubMed ID: 7683247
[TBL] [Abstract][Full Text] [Related]
59. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial.
Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS
Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016
[TBL] [Abstract][Full Text] [Related]
60. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
Jørgensen AP; Ueland T; Sode-Carlsen R; Schreiner T; Rabben KF; Farholt S; Høybye C; Christiansen JS; Bollerslev J
J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
